Show simple item record

dc.contributor.authorAyomide, Olobatoke Tunde
dc.contributor.authorKyaruzi, Victor Meza
dc.contributor.authorMugenyi, Nathan
dc.contributor.authorNaeem, Ahmed
dc.contributor.authorShituluka, Musakanya
dc.contributor.authorIkwuegbuenyi, Chibuikem A
dc.contributor.authorOyesiji, Emmanuel
dc.contributor.authorElamin, Zobidah Yousif
dc.contributor.authorDavid, Samuel Oreoluwa
dc.contributor.authorMduma, Emmanuel
dc.contributor.authorShimber, Emnet
dc.contributor.authorAzouz, Heba Mohamed
dc.contributor.authorGankpe, Fortune
dc.contributor.authorEsene, Ignatius
dc.contributor.authorTirsit, Abenezer
dc.date.accessioned2024-10-10T12:54:29Z
dc.date.available2024-10-10T12:54:29Z
dc.date.issued2024
dc.identifier.citationAyomide, O. T., Kyaruzi, V. M., Mugenyi, N., Naeem, A., Shituluka, M., & Ikwuegbuenyi, C. A. (2024). The Neuroprotective Efficiency of Cysteinyl Leukotriene Receptor Antagonist (Montelukast) in TBI; A Systematic Review and Meta-Analysis Protocol. Ann Surg Protoc, 1(1), 1002.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/3870
dc.description.abstractBackground: Traumatic Brain Injury (TBI) is one of the leading causes of morbidity, disability, and mortality across all ages, with a global annual incidence between 27 to 69 million. The pathophysiology of TBI involves the over-production of reactive oxygen species. This systematic review aims to evaluate the efficacy of montelukast in patients with TBI. Methodology: This systematic review aims to evaluate the neuroprotective efficacy of montelukast, a cysteinyl leukotriene receptor antagonist, in Traumatic Brain Injury (TBI) patients. The study will be conducted following the AMSTAR guidelines and reported according to PRIMA guidelines. A comprehensive literature search will be conducted in various databases, including Pubmed, Embase, Hinari, Cochrane Central Register of Controlled Trials, WHO International Clinical Trials Registry Platform, and clinicaltrials.gov, using keywords related to leukotriene receptor antagonists and TBI. The inclusion criteria for the studies will be randomized controlled trials in human subjects that compare montelukast with a placebo or montelukast with routine treatment. Two independent reviewers will screen the titles and abstracts of the studies identified by the search and obtain full-text articles for those that meet the inclusion criteria. The quality of the included studies will be evaluated using the Cochrane Risk of Bias tool or ROBIN. Data will be extracted from the studies using Eppi Reviewer or Microsoft Excel. A narrative synthesis of the data will be conducted, and a meta-analysis will be performed if appropriate. Ethics and dissemination: This research will utilize previously collected data, and no individuals will be involved. Therefore, obtaining ethical clearance is not required. The findings of this study will be presented at national and international conferences and submitted for publication in a journal undergoing peer review.en_US
dc.language.isoen_USen_US
dc.publisherAnnals of Surgery Protocolsen_US
dc.subjectTraumatic brain injuryen_US
dc.subjectMontelukasten_US
dc.subjectCysteinyl leukotriene receptor antagonisten_US
dc.subjectNeuroprotectionen_US
dc.subjectRandomized controlled trialen_US
dc.subjectSecondary data analysisen_US
dc.subjectMeta-analysisen_US
dc.subjectLeukotriene receptor antagonisten_US
dc.subjectTBIen_US
dc.subjectCochrane risk of bias toolen_US
dc.titleThe Neuroprotective Efficiency of Cysteinyl Leukotriene Receptor Antagonist (Montelukast) in TBI; A Systematic Review and Meta-Analysis Protocolen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record